     |
 |
Latest Personal Injury News Pfizer Suspends Sales of BextraŽ
Source:
April 7, 2005
At the request of U.S. and European regulators, Pfizer today suspended sales of the Cox-2 inhibitor drug Bextra® stating the potentially dangerous side effects had eclipsed the painkiller benefits. In their announcement the Food and Drug Administration (FDA) emphasized Bextra® provides little to no added value as a painkiller yet its use can result in a life-threatening skin condition called Stevens-Johnson syndrome. The syndrome begins as an allergic reaction with blistering of the mouth and lips which then quickly spreads to the rest of the body. Bextra® is in the same class of drugs as Merck & Co.'s withdrawn Vioxx®. Vioxx® was recalled on September 30, 2004. For information on how Goldberg & Osborne can evaluate a potential Bextra lawsuit, click here. << Back to News |